Other News Releases in Health Care & Hospitals
Congressman Fattah: Thanks to Specter, Casey for a Major Step Along History's Path
Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure
Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill
Other News Releases in Surveys, Polls and Research
Rentrak Announces Box Office Numbers for Weekend of November 20, 2009
Fandango Sells a Record-Breaking 18% of 'New Moon' Opening Weekend Box Office
U.S. Census Bureau Daily Feature for Nov. 22
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Tobacco, Surveys, Polls and Research
Promising New Drug and Other Trends To Double Smoking Cessation and Addiction Treatments Market by 2010
NEW YORK, May 30 /PRNewswire/ -- With the advent of a possible new
blockbuster drug and greater reimbursement levels for the treatment of
nicotine, alcohol, and drug addictions, global sales of smoking cessation
and addiction treatments are expected to rise from revenues of little over
$1.1 billion in 2005 to more than $2.3 billion in 2010, according to
Smoking Cessation and Addiction Treatments: A World Market Analysis, a new
study released today from Kalorama Information.
Nicotine is clearly the most abused drug worldwide, with over 1.4
billion incidences, including 50 million users in the U.S. alone. Smoking
cessation has continually become a particular focus of global health
agencies, and the increasing high awareness of effective smoking cessation
products have helped to drive market growth.
The market now dominated by GlaxoSmithKline with its Zyban smoking
cessation treatment, and Schering-Plough / Reckitt Benckiser with their
Suboxone/Subetex substance abuse treatment, is primed for a dramatic change
as Pfizer moves into smoking cessation.
"We believe Pfizer's Chantix will acquire the largest share of the
market, overtaking GlaxoSmithKline in smoking cessation, and leading all
addiction treatments based on the superior effectiveness of Pfizer's
product in clinical studies," notes Melissa Elder, the report's author. "To
a more limited extent, new drugs in alcohol and substance abuse treatments
will also change those markets."
Smoking Cessation and Addiction Treatments: A World Market Analysis
includes world incidence and data for nicotine addiction, drug addiction,
and alcohol abuse; current and forecasted revenues through 2010; current
and forecasted market share with consideration of new players in the
market; reviews of current products and new products in the pipeline; and
key trends driving pharmaceutical treatments for smoking cessation and
drug/alcohol addiction. It can be purchased directly from Kalorama
Information by visiting
http://www.kaloramainformation.com/Smoking-Cessation-Addiction-1460041. It
is also available at MarketResearch.com.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the
latest in independent market research on medical markets. For more
information, contact Tom Ehart at 240-747-3014 or
tehart@marketresearch.com' target='_blank' title='tehart@marketresearch.com'>tehart@marketresearch.com, or visit www.KaloramaInformation.com.
Contact:
Tom Ehart
MarketResearch.com
240-747-3014
tehart@marketresearch.com' target='_blank' title='tehart@marketresearch.com'>tehart@marketresearch.com
SOURCE Kalorama Information













